ANDRE JUICE (02218) intends to acquire part of the shares of shareholdings of JIANGQI HE, QIANG YUAN, and Ningbo Yuanluizai Technology Partnership Enterprise (Limited Partnership) in Ningbo Strong Technology.

22:56 15/06/2026

Andi Fruit Juice (02218) announced that the company convened the tenth meeting of the ninth board of directors on June 15, 2026, and passed a resolution to sign the "Equity Transfer Framework Agreement" to acquire a portion of the shares of Jiangqi He, Qiang Yuan, and Ningbo Yuanluo Technology Partnership Enterprise (Limited Partnership) of Ningbo Yongqiang Technology Co., Ltd. using the company's own or self-raised funds.

The notice released by ANDRE JUICE (02218) states that the company held the tenth meeting of the ninth board of directors on June 15, 2026, and approved the proposal on signing the , regarding the acquisition of a portion of the equity of Jiangqi He, Qiang Yuan, and Ningbo Yuanqiang Technology Co., Ltd. (hereinafter referred to as "Yuanqiang Technology") by the company using its own or self-raised funds. Jiangqi He, Qiang Yuan, and Ningbo Yuanluzai Technology Partnership Enterprise (Limited Partnership) agreed to cooperate with the company in communicating with other shareholders of the target company, ultimately achieving the goal of acquiring control of the target company. The acquisition of control of the target company is a prerequisite for this transaction. The total consideration for this transaction is preliminarily estimated to be 600-800 million RMB, subject to the final evaluation value. It is preliminarily estimated that this transaction will not constitute a major asset restructuring. The target company is a high-tech enterprise specializing in the research, production, and sales of integrated circuit electronic interconnect materials. The target company has a production capacity of 10 million square meters per year of high-speed and high-frequency BT-type substrate electronic interconnect materials in the Integrated Circuit Industry Agglomeration Base in Beilun District, Ningbo City. The target company has established a closed-loop ecological system from design, packaging, system, to substrate materials. Its direct customers include Victory Giant Technology, Shennan Circuits, Hushik Electronics, Shengyi Electronics, Founder Technology Group, DELTON, Shenzhen Fastprint Circuit Tech, Yuya Semiconductor, etc., and end customers include Inspur Electronic Information Industry, Dawning Information Industry, Xinhua Three, Zhongji Innolight, etc. The main products of the target company are electronic interconnect materials, including copper-clad laminates and semi-cured sheets. Copper-clad laminate is a type of board material made by impregnating electronic glass fiber cloth or other reinforcing materials with resin, covering one or two sides with copper foil, and then making it with heat and pressure. It has good dielectric and mechanical properties. Complementary to this, semi-cured sheets are important semi-finished products in the production of copper-clad laminates, made by the combination of resin and reinforcing materials through professional processes. Electronic interconnect materials are core materials for making printed circuit boards, which are carriers for electrical connections of electronic components and important components in modern electronic information products.

New stock news | Din Tai Pharmaceuticals once again submits an application to the Hong Kong Stock Exchange, becoming the largest CRO in the field of non-clinical research for Chinese cardiovascular and metabolic diseases.

EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.

New Stock News | Lico Pharmaceuticals files second application to Hong Kong Stock Exchange for the development of small molecule inhibitors for the treatment of autoimmune and inflammatory diseases.

EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.

New Stock News | Lico Pharmaceuticals files second application to Hong Kong Stock Exchange for the development of small molecule inhibitors for the treatment of autoimmune and inflammatory diseases.